University of Groningen
Pharmacological approaches to optimize TB treatment
Zuur, Marlies
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Zuur, M. (2018). Pharmacological approaches to optimize TB treatment: An individualized approach. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Chapter
Curriculum vitae
Marlies Anke (Marlanka) Zuur was born on January 15, 1993 in Smallingerland, Friesland. In 2011 she finished high school at OSG Sevenwolden in Heerenveen, where after she started studying pharmacy at the University of Groningen. For her bachelorthesis she researched the influence of the Prostaglandine E2 – EPAC signaling pathway on the epithelial-to-mesynchymal cell transition in non-small cell lung cancer cells. Hereafter she wanted to get into a PharmD/PhD program at the University Medical Center Groningen, however it was not an official program at the time. She became a PhD candidate while doing her masterthesis on the optimization of TB treatment in 2016. She graduated Cum Laude in 2017 and started with her first job as a pharmacist at the unit clincal pharmacy and pharmacology, subdivision support clinical trials at the University Medical Center Groningen directly after.
About the author
List of publications
1. Zuur MA, van Asselt ADI, van ‘t Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC. Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. Int. J. Tuberc. Lung Dis. 2018;22(9):991-999.
2. Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC. Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes. Clin. Infect. Dis. 2018
3. Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC. Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients. Antimicrob. Agents Chemother. 2018;62(5). pii: e02250-17. 4. van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange
WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis. Antimicrob. Agents Chemother. 2017;61(4). pii: e01783-16.
5. Zuur MA, Akkerman OW, Davies Forsman L, Hu Y, Zheng R, Bruchfeld J, Tiberi S, Migliori GB, Alffenaar JC. Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe? Eur. Respir. J. 2016;48(4):1230-1233.
6. Zuur MA, Akkerman OW, Touw DJ, van der Werf TS, Cobelens F, Burger DM, Grobusch MP, Alffenaar JW. Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.
Eur. Respir. J. 2016;48(3):932-4.
7. Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JW. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Expert Opin.
Drug Metab. Toxicol. 2016;12(5):509-21.
